Navigation Links
ASH awards Timothy J. Ley, M.D., with 2012 E. Donnall Thomas Lecture and Prize
Date:8/27/2012

Dr. Ley will present his lecture, "The AML Genome," at 9:00 a.m. on Monday, December 10, 2012, at the 54th ASH Annual Meeting and Exposition in Atlanta. His lecture will explore the use of whole genome sequencing in AML, which has offered an unprecedented view of the mutations that cause this disease. His lecture will also focus on next-generation DNA sequencing approaches in AML that are providing detailed information about the clonal architecture of AML at presentation and its evolution at relapse, as well as new clues regarding the genetic underpinnings of drug resistance and disease progression.

Dr. Ley has played a pivotal role in advancing the translational field of cancer genomics, specifically relating to hematologic malignancies, as he has spent his career studying stem cell, T-cell, and leukemic genetics and biology. At Washington University, he holds the Lewis T. and Rosalind B. Apple Chair in Oncology, serves as chief of the Section of Stem Cell Biology in the Division of Oncology, and is Professor of Medicine and Genetics. Dr. Ley also serves as associate director of The Genome Institute (for Cancer Genomics) and directs the Embryonic Stem Cell Core at Washington University's Siteman Cancer Center.

In collaboration with Drs. Richard Wilson and Elaine Mardis at the Genome Institute at Washington University, Dr. Ley and colleagues were the first to sequence a cancer genome (from a patient with AML), and their investigations have provided important new insights into the origin and evolution of AML mutations. These findings have introduced a new, unbiased method for discovering cancer-initiated mutations in previously unidentified genes that may respond to targeted therapies. By highlighting the diversity of mutations in AML, Dr. Ley's breakthrough work in cancer genomics has demonstrated that most AML mutations are benign, background events that arise in hematopoietic stem cells as a function of aging, and that only a handful of mutations contribute to pathogenesis in each case.

Dr. Ley is also responsible for creating the first mouse model of acute promyelocytic leukemia (APL), a subtype of AML, and his group was the first to sequence a mouse cancer genome, using this model of leukemia. The model demonstrated that APL is caused by an initiating event that requires cooperating mutations to cause the disease, and it has provided key insights into the molecular mechanisms of this disorder in humans, since many of the cooperating mutations are conserved between species.

"The Society is honored to present this award to Dr. Ley for his many contributions to hematology and genetics, especially within the exciting field of genome sequencing," said ASH President Armand Keating, MD, of Princess Margaret Hospital in Toronto. "Through his identification of the genetics of leukemia development and relapse, Dr. Ley has discovered new pathways for targeted and individualized cancer therapies, which will help countless patients who suffer from blood cancers around the world."

Dr. Ley holds many prestigious awards and honors from ASH and other organizations. In addition to receiving the 2008 ASH Mentor Award in Basic Science and serving as a past chair of the ASH Committee on Scientific Affairs, Dr. Ley is the recipient of a National Institutes of Health (NIH) Merit Award. He currently serves as chair of NIH's National Human Genome Research Institute Board of Scientific Counselors and is also a past president of the American Society for Clinical Investigation, a fellow of the American Association for the Advancement of Science and the American Academy of Arts and Sciences, and a member of the Institute of Medicine.


'/>"/>
Contact: Claire Gwayi-Chore
cgwayi-chore@hematology.org
202-776-0544
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. NIH awards $7.8 million for innovative HIV vaccine approaches
2. National Hartford Centers of Gerontological Nursing Excellence awards new fellows, scholars
3. ASTRO awards 5 research grants
4. State stem cell research funding agency awards $20 million to UCI, StemCells Inc.
5. Prevention of HIV spread focus of NIDAs 2012 Avant-Garde Awards
6. Klerman/Freedman Awards
7. Damon Runyon Cancer Research Foundation grants fellowship awards to 21 top young scientists
8. AOSSM presents annual research awards
9. U-Ms Taubman Institute awards inaugural $100,000 translational medical research prize
10. Standard Process Inc.’s Marketing Team Wins Six Awards
11. NIH awards $6.1 million grant to GUMC to establish Center of Excellence for Health Disparities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology: